7 local hospitals trying phase III clinical studies for Sutent.

Published: 2007-07-13 06:58:00

Updated: 2007-07-13 06:58:00

Pfizer planned a phase III clinical study of Sutent (sunitinib malate) for the metastatic colorectal cancer (mCRC) patients to evaluate its safety and efficacy in combination with the conventional chemotherapy.

Earlier this, a phase I clinical study was recently presented at the conference of ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK